At the International Myeloma Society meeting over the weekend in Glasgow, Scotland, UK IASO released its first data on two assets to treat relapsed / refractory multiple myeloma. A group of 10 patients, receiving a single infusion of IASO206 (a BCMA-targeted CAR-T cell therapy), showed a robust expansion of CAR-positive T cells, with peak between 12 and 21 days, but detectable up to six months after treatment. IASO206, administered without apheresis or lymphodepleting chemo, achieved a 90% objective response rate, increasing to 100% in the higher dose cohort. In a second data release in 9 patients, IASO announced RD140, a fully human BCMA/GPRC5D dual-targeted FasT CAR-T cell therapy, showed an 88.9% objective response rate, again hitting 100% in the higher dose cohort. RD140 was built on the FasT CAR-T platform, with cell manufacturing in 3-4 days.